Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 4/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128211 | 0.86 | CYP2C19 (0.45) | NAMPTLMNAHTTSMN1; SMN2CASP1 | |
| SCHEMBL5936713 | 0.84 | MMP8 (0.50) | LMNASMN1; SMN2MAPTGAAKMT2A | |
| SCHEMBL5780313 | 0.84 | MMP8 (0.50) | LMNASMN1; SMN2MAPTGAAKMT2A | |
| SCHEMBL28532831 | 0.83 | CYP19A1 (0.49) | NAMPTLMNAHTTSMN1; SMN2CASP1 | |
| SCHEMBL10165351 | 0.83 | KMT2A (0.46) | LMNAHTTSMN1; SMN2MAPTGAA | |
| SCHEMBL14445303 | 0.82 | GAA (0.47) | LMNASMN1; SMN2CASP1CYP19A1CYP17A1 | |
| SCHEMBL23886510 | 0.82 | NAMPT (0.46) | NAMPTLMNAHTTSMN1; SMN2CASP1 | |
| SCHEMBL23535218 | 0.81 | L3MBTL1 (0.45) | LMNAHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL16893443 | 0.80 | ALOX15 (0.45) | LMNAHTTMAPTGAAKMT2A | |
| SCHEMBL6141592 | 0.78 | NAMPT (0.42) | NAMPTLMNACASP1CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3541786-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-25 | — | — | EP | disclosed |
| CN-110278711-A | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | 百时美施贵宝公司 | 2019-09-24 | — | — | CN | disclosed |
| WO-2018089402-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089402-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | NAMPT 2491/4885LMNA 3927/4885HTT 4328/4885 |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | NAMPT 2491/4885LMNA 3927/4885HTT 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.